Posted by Michael Wonder on 28 Nov 2024
European Commission approves Pfizer’s Hympavzi (marstacimab) for the treatment of adults and adolescents with severe haemophilia A or B without inhibitors
20 November 2024 - In the EU, Hympavzi is the first once weekly subcutaneous treatment approved for eligible people living with severe haemophilia B and the first to be administered via a pre-filled pen or syringe for people living with severe haemophilia A or B.
Pfizer announced today that the European Commission has granted marketing authorisation for Hympavzi (marstacimab) for the routine prophylaxis of bleeding episodes in patients 12 years of age and older weighing at least 35 kg with severe haemophilia A (congenital factor VIII [FVIII] deficiency, FVIII <1%) without FVIII inhibitors or severe haemophilia B (congenital factor IX (FIX) deficiency, FIX <1%) without FIX inhibitors.
